|
Delayed
London S.E.
05:51:02 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 146.00 GBX | +1.04% |
|
-4.58% | +14.06% |
| 07-29 | Diaceutics PLC Reports Revenue Results for the Half Year Ended 30 June 2026 | CI |
| 06-02 | Diaceutics PLC, 2025 Earnings Call, May 26, 2026 |
Company Valuation: Diaceutics PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 85.75 | 63.68 | 73.32 | 106.1 | 108.7 | 122.7 | - | - |
| Change | - | -25.74% | 15.14% | 44.67% | 2.47% | 12.85% | - | - |
| Enterprise Value (EV) 1 | 66.08 | 43.84 | 56.65 | 93.32 | 101.3 | 114.9 | 110.6 | 102.7 |
| Change | - | -33.66% | 29.24% | 64.73% | 8.6% | 13.35% | -3.76% | -7.12% |
| P/E | - | 89.9x | -42x | -62.1x | - | - | - | - |
| PBR | - | 1.53x | 1.8x | 2.66x | 2.67x | 2.98x | 2.65x | 2.19x |
| PEG | - | - | 0x | 25.71x | - | - | - | - |
| Capitalization / Revenue | 6.15x | 3.26x | 3.09x | 3.3x | 2.83x | 2.63x | 2.18x | 1.83x |
| EV / Revenue | 4.74x | 2.25x | 2.39x | 2.9x | 2.64x | 2.46x | 1.96x | 1.53x |
| EV / EBITDA | 28.1x | 12.2x | 24x | 22.2x | 13.4x | 11.2x | 8.04x | 5.66x |
| EV / EBIT | 120x | 76.4x | -18.8x | -38x | 57.5x | 35.9x | 18.6x | 10.3x |
| EV / FCF | -13.1x | 194x | -16x | -23.4x | -19.2x | 232x | 21.9x | 14.1x |
| FCF Yield | -7.61% | 0.52% | -6.26% | -4.27% | -5.2% | 0.43% | 4.57% | 7.07% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 1 |
| Rate of return | - | - | - | - | - | - | - | 69.2% |
| EPS 2 | - | 0.0084 | -0.0207 | -0.0202 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 13.94 | 19.5 | 23.7 | 32.16 | 38.44 | 46.72 | 56.34 | 67.09 |
| EBITDA 1 | 2.349 | 3.583 | 2.357 | 4.206 | 7.573 | 10.25 | 13.76 | 18.15 |
| EBIT 1 | 0.55 | 0.574 | -3.018 | -2.455 | 1.761 | 3.2 | 5.95 | 10 |
| Net income 1 | 0.561 | 0.724 | -1.746 | -1.703 | 0.097 | -1.1 | 1.5 | 4.3 |
| Net Debt 1 | -19.68 | -19.84 | -16.67 | -12.74 | -7.344 | -7.78 | -12.1 | -19.97 |
| Reference price 2 | 1.020 | 0.755 | 0.870 | 1.255 | 1.280 | 1.445 | 1.445 | 1.445 |
| Nbr of stocks (in thousands) | 84,069 | 84,339 | 84,274 | 84,515 | 84,912 | 84,881 | - | - |
| Announcement Date | 3/22/22 | 4/17/23 | 5/21/24 | 5/13/25 | 5/26/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 2.46x | 11.2x | -.--% | 166M | |
| -94.87x | 23.95x | 59.96x | -.--% | 69.91B | |
| -12.65x | 7.02x | 17.08x | - | 3.81B | |
| 32.91x | 2.45x | 21.13x | 1.44% | 3.6B | |
| 94.1x | 12.6x | 19.64x | 0.28% | 3.37B | |
| 30.11x | 4.06x | 16.18x | 0.59% | 1.4B | |
| Average | 9.92x | 8.76x | 24.20x | 0.46% | 13.71B | |
| Weighted average by Cap. | -75.56x | 21.38x | 53.78x | 0.09% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXRX Stock
- Valuation Diaceutics PLC
Select your edition
All financial news and data tailored to specific country editions
